25 May 2013
Keywords: shire, david, pendergast, retire, end, basingstoke, uk-based
Article | 26 March 2007
Basingstoke, UK-based drugmaker Shire says that David Pendergast, president of its human genetic therapies business, is to retire at the
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
26 March 2007
19 March 2007
24 May 2013
© 2013 thepharmaletter.com